Latest CAVATAK(TM) Stories
SYDNEY, Jan. 30, 2014 /PRNewswire/ -- Highlights: -- Transformational capital raising of up to $27.1m at $0.28 per share enabling Viralytics to complete 3 key CAVATAK(TM) clinical trials and to advance more rapidly to commercialisation -- Viralytics to be fully funded until the end of 2016 -- Strengthens balance sheet ahead of potential commercial negotiations -- Binding commitments to raise $23.0 million via two tranche placement. $6.1m via...
- A punctuation mark (/) used to separate related items of information.
- A little rod; a twig.